Cognivia Raises €15.5M to Advance AI-Driven Clinical Trial Innovations.
Cognivia leverages a combination of patient psychology quantification and advanced machine learning to revolutionize clinical trials, aiming to optimize therapeutic outcomes and accelerate drug development
Company Name: Cognivia
Location: Mont-Saint-Guibert, Belgium
Sector: Healthcare/AI
Funding Details: Raised €15.5M from Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d’Investissement), and WE (Wallonie Entreprendre).
Purpose of Investment: To deploy predictive clinical trial solutions that enhance the speed and effectiveness of developing new treatments by understanding the relationship between patient traits and treatment outcomes.
Leadership: Led by CEO Dominique Demolle.
Product: Cognivia’s AI and ML technologies integrate quantitative psychological data to improve the efficacy measurement in clinical trials, predicting patient behavior and treatment response.
About Company: Cognivia leverages a combination of patient psychology quantification and advanced machine learning to revolutionize clinical trials, aiming to optimize therapeutic outcomes and accelerate drug development.
